文献速递生殖医学

激动剂触发周期中优化黄体支持方案:一项随机临床试验

Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
PubMed 文献 · Hum Reprod · 2018-01-01

在这项纳入190例高反应ICSI患者的随机对照开放标签试验中,GnRH激动剂触发配合专用黄体支持方案(取卵时1500 IU hCG加口服雌二醇和肌注黄体酮)的持续妊娠率与hCG触发(5000 IU hCG加口服雌二醇和阴道黄体酮)相当,但中重度OHSS发生率可能更低。

要点

  • GnRH激动剂触发配合专用黄体支持方案的持续妊娠率与hCG触发相当(51.6% vs 52.6%,P=0.88)。
  • hCG触发组中重度OHSS发生率高于GnRH激动剂触发组(14% vs 5%,P=0.047)。
  • 触发日≥11 mm卵泡数是OHSS的唯一独立预测因素(P=0.0004)。

核心结论

  • 在拮抗剂ICSI周期中,GnRH激动剂触发配合专用黄体支持方案的持续妊娠率与hCG触发相当,但中重度OHSS发生率可能更低。

研究设计与样本

  • 随机对照开放标签试验,2015年6月至2016年3月在一家私立生育中心招募190例预测高反应的女性,随机分为两组各95例:A组GnRH激动剂触发,取卵时给予1500 IU hCG,黄体期口服雌二醇加肌注黄体酮;B组5000 IU hCG触发,黄体期口服雌二醇加阴道黄体酮。

主要发现

  • 每随机患者的持续妊娠率A组49/95(51.6%)vs B组50/95(52.6%),P=0.88,RR=0.980(95%CI:0.75-1.29)。
  • 中重度OHSS发生率B组13/95(14%)vs A组5/95(5%),P=0.047(未校正卡方检验)。
  • 多因素回归分析预测OHSS时,触发日≥11 mm卵泡数是唯一独立预测因素(P=0.0004)。

关键数值与推荐

  • 作者推荐对接受IVF/ICSI的高反应且OHSS高风险患者使用GnRH激动剂触发加专用黄体期支持方案。

临床怎么用

  • 作者推荐对接受IVF/ICSI的高反应且OHSS高风险患者使用GnRH激动剂触发加专用黄体期支持方案,该方案持续妊娠率与hCG触发相似,且中重度OHSS发生率可能更低。

局限性

  • 严格的选择标准限制了结果的推广。
  • 研究把握度基于妊娠率而非OHSS,因此OHSS预测的证据强度较弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: In ICSI patients with high risk of ovarian hyperstimulation syndrome (OHSS), are antagonist cycles triggered by gonadotropin releasing hormone (GNRH) agonist with a specialized luteal support regimen associated with comparable ongoing pregnancy rate (OPR) and less OHSS than those triggered by hCG? SUMMARY ANSWER: In antagonist ICSI cycles, GnRH agonist triggering with a specialized luteal support regimen is associated with comparable OPR to those triggered by hCG but may be less likely to be associated with OHSS. WHAT IS KNOWN ALREADY: In IVF/ICSI protocols, exogenous hCG was used for years as a substitute of the endogenous LH surge. However, because of its longer half life, hCG is associated with more risk of OHSS, especially in high risk women. For this reason, GnRH agonist triggering was introduced. There is, however, no consensus on the best protocol for luteal support on agonist triggered cycles. STUDY DESIGN, SIZE, DURATION: Randomized controlled open label trial including 190 participants recruited from June 2015 to March 2016 in a private fertility center. Participants were divided into 2 equal groups; GnRH agonist trigger and hCG trigger. Randomization was done using identical sealed envelope technique. PARTICIPANTS/MATERIALS, SETTING, METHODS: One hundred ninety women, predicted to have high response, were randomized on the day of final oocyte maturation into two equal groups: group (A), GnRH agonist trigger followed by specialized regimen (1500 IU hCG) at time of oocyte retrieval plus oral estradiol and intramuscular progesterone during luteal phase; and group (B), 5000 IU of hCG with luteal support (oral estradiol and vaginal progesterone). MAIN RESULTS AND THE ROLE OF CHANCE: The 2 groups were comparable in baseline characteristics. OPR per randomized patient was comparable in the 2 groups {49/95 (51.6%) in group A, and 50/95 (52.6%) in group B ((P = 0.88); RR = 0.980, 95% CI: 0.75-1.29)}. Considerable (moderate + severe) OHSS was higher in group B (13/95 [14%] versus 5/95 [5%] P = 0.047; uncorrected Chi-square test). Upon performing multivariate regression analysis for predicting OHSS, number of follicles ≥11 mm on trigger day was the only independent predictor (P = 0.0004). LIMITATIONS, REASONS FOR CAUTION: Strict selection criteria limit generalization of results. The study was powered for pregnancy rate not OHSS, so that the strength of evidence on OHSS prediction is weak. WIDER IMPLICATIONS OF THE FINDINGS: We recommend the use of GnRH agonist plus the specialized luteal phase support in high responders with high risk of OHSS undergoing IVF/ICSI cycles. This protocol achieved a similar ongoing pregnancy to hCG triggering and may be less likely to result in moderate to severe OHSS. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: PACTR 201506001132105. TRIAL REGISTRATION DATE: 24/6/2015. DATE OF FIRST PATIENT’S ENROLLMENT: 26/6/2015.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Elgindy EA, Sibai H, Mostafa MI, et al. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial. Hum Reprod. 2018. PMID: 29562260. doi:10.1093/humrep/dey054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。